FINANCINGS

Adma Biologics Inc. said it entered a loan and security agreement with Oxford Finance LLC for up to $21 million.

Advanced Accelerator Applications SA completed a capital increase of $26 million.

Alder Biopharmaceuticals Inc. priced a public offering for gross proceeds of about $200 million.

Ankasa Regenerative Therapeutics Inc. has received the first tranche of $8.5 million in a $17 million series A round of financing.

Benitec Biopharma Ltd. filed to raise up to $70 million in an IPO of American depository shares.

Biopharmx Corp. raised $10 million in its IPO, seliing approximately 3.6 million shares at $2.75.

Bluebird Bio Inc. priced a public offering of 2.9 million shares of its common stock at $170 per share.

Catabasis Pharmaceuticals Inc. priced its IPO, generating $60 million from the sale of 5 million common shares at $12 each.

Celyad SA completed an IPO on Nasdaq grossing $100 million.

Clementia Pharmaceuticals Inc. completed a $60 million mezzanine financing round.

Conkwest Inc. filed its S-1 registration with the SEC to raise up to $172.5 million in an IPO.

Dipexium Pharmaceuticals Inc. priced a public offering with gross proceeds expected to be approximately $18.5 million.

Highland Therapeutics Inc. completed a $50 million financing.

Impax Laboratories Inc. priced $500 million of its 2 percent convertible senior notes due 2022 in a private offering.

Nabriva Therapeutics AG has filed to generate up to $92 million in an IPO of American depositary shares.

Nivalis Therapeutics Inc. closed its IPO for aggregate proceeds of $88.55 million.

Oxford Science Innovation plc has closed its first fund at $505.7 million.

Pluristem Therapeutics Inc. expects to raise $17 million from a registered direct offering of 6.8 million shares of common stock and and warrants.

Provectus Biopharmaceuticals Inc. priced a public offering for gross proceeds of approximately $13.1 million.

Viratherapeutics GmbH raised $4 million in a first closing of a series A round.

Western Oncolytics Ltd. has raised $2.5 million from a series A round.

DEALS

3SBio Inc. said it acquired the ex-China global rights to Apexigen Inc.'s anti-TNF monoclonal antibody technology.

Biontech AG is collaborating with Siemens AG to construct a fully automated and digitalized production site for its personalized cancer vaccines.

BRIM Biotechnology Inc. is collaborating with Janssen Pharmaceutica NV on the development and commercialization of compounds identified by Janssen for dengue fever indications.

Pfizer Inc. is acquiring two meningitis vaccines from Glaxosmithkline plc for about $130 million.

. . . AND MORE

Forum Pharmaceuticals Inc. received FDA fast track status to encenicline, an alpha 7 agonist in phase III development to treat cognitive impairment in schizophrenia and Alzheimer's disease.

Plasmatech Biopharmaceuticals Inc. changed its name to Abeona Therapeutics Inc.

Primegen Biotech LLC launched a subsidiary, Vetcell Therapeutics, to develop therapies for pets and companion animals using different types of stem cells.

The Medicines Co.'s antiplatelet therapy cangrelor gained FDA approval to prevent blood clots in patients undergoing percutaneous coronary intervention or angioplasty.